Trial Profile
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG - PET/MRI of Primary Central Nervous System Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary) ; Fludeoxyglucose F-18 (Primary)
- Indications CNS cancer; Non-Hodgkin's lymphoma
- Focus Diagnostic use
- 03 Jan 2024 Status changed from recruiting to completed.
- 15 Dec 2021 Planned End Date changed from 1 Dec 2023 to 31 Dec 2023.
- 15 Dec 2021 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2022.